Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality

Although natural killer (NK) cells have been studied in connection with dendritic cell (DC)-based vaccination in the field of cancer immunology, their role has barely been addressed in the context of therapeutic vaccination against HIV-1. In this study, we evaluated whether a therapeutic DC-based vaccine consisting of monocyte-derived DCs electroporated with Tat, Rev and Nef encoding mRNA affects NK cell frequency, phenotype and functionality in HIV-1-infected individuals. Although the frequency of total NK cells did not change, we observed a significant increase in cytotoxic NK cells following immunisation. In addition, significant changes in the NK cell phenotype associated with migration and exhaustion were observed together with increased NK cell-mediated killing and (poly)functionality. Our results show that DC-based vaccination has profound effects on NK cells, which highlights the importance of evaluating NK cells in future clinical trials looking at DC-based immunotherapy in the context of HIV-1 infection.

Automated summary

This study evaluated the effects of a therapeutic DC-based vaccine consisting of monocyte-derived DCs electroporated with HIV-1 Tat, Rev and Nef encoding mRNA on NK cell frequency, phenotype and functionality in HIV-1-infected individuals. The results showed a significant increase in cytotoxic NK cells, changes in NK cell phenotype associated with migration and exhaustion, as well as improved NK cell-mediated killing and (poly)functionality following immunisation. These findings highlight the importance of evaluating NK cells in future clinical trials of DC-based immunotherapy in the context of HIV-1 infection.